Acute Myeloid Leukemia
Phase II study to evaluate Xanafide in combination with ara-C for secondary AML
Published in Clinical Oncology Week, November 21st, 2005
The phase II study will be conducted at multiple centers in North America and is expected to enroll up to 60 patients with secondary AML, patients with antecedent myelodysplastic syndrome or prior exposure to leukemogenic therapy. Patients will receive a daily dose of Xanafide for 5 days in combination with a standard dose of ara-C as a continuous infusion for 7 days. The primary endpoint of the study is the rate of complete remission, and secondary...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Cancer Therapy
Progressive muscle relaxation training reduced chemotherapy side effects - Diagnostics
Digital rectal examination cited as barrier to prostate cancer screening - Palliative Care
Methotrimeprazine used in management of nausea and vomiting in advanced cancer - Prognostics
Age and race should not be used as factors in prostate cancer treatment decision-making - Prognostics
Circulating plasma cells predicted survival in patients with newly diagnosed multiple myeloma - Apoptosis
Accumulation of p53 sensitizes human cells to tumor necrosis factor alpha-induced apoptosis - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
